[HTML][HTML] Cancer immune evasion through loss of MHC class I antigen presentation

K Dhatchinamoorthy, JD Colbert, KL Rock - Frontiers in immunology, 2021 - frontiersin.org
Major histocompatibility class I (MHC I) molecules bind peptides derived from a cell's
expressed genes and then transport and display this antigenic information on the cell …

[HTML][HTML] Growth/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint

J Wischhusen, I Melero, WH Fridman - Frontiers in Immunology, 2020 - frontiersin.org
Growth/differentiation factor-15 (GDF-15), also named macrophage inhibitory cytokine-1, is a
divergent member of the transforming growth factor β superfamily. While physiological …

[HTML][HTML] Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy

AE Vilgelm, A Richmond - Frontiers in immunology, 2019 - frontiersin.org
Chemokines are small secreted proteins that orchestrate migration and positioning of
immune cells within the tissues. Chemokines are essential for the function of the immune …

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM

AL Hung, R Maxwell, D Theodros, Z Belcaid… - …, 2018 - Taylor & Francis
The use of inhibitory checkpoint blockade in the management of glioblastoma has been
studied in both preclinical and clinical settings. TIGIT is a novel checkpoint inhibitor recently …

[HTML][HTML] Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion

P Dong, Y Xiong, J Yue, SJB Hanley, H Watari - Frontiers in oncology, 2018 - frontiersin.org
Although the role of PD-L1 in suppressing the anti-tumor immune response is extensively
documented, recent discoveries indicate a distinct tumor-intrinsic role for PD-L1 in …

[HTML][HTML] YTHDF1 regulates tumorigenicity and cancer stem cell-like activity in human colorectal carcinoma

Y Bai, C Yang, R Wu, L Huang, S Song, W Li… - Frontiers in …, 2019 - frontiersin.org
YTH N6-methyladenosine (m6A) RNA binding protein 1 (YTHDF1) is a core factor in RNA
methylation modification. Recent studies have shown that m6A is closely related to multiple …

Targeting m6A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer

Y Bao, J Zhai, H Chen, CC Wong, C Liang, Y Ding… - Gut, 2023 - gut.bmj.com
Objective The role of N6-methyladenosine (m6A) in tumour immune microenvironment
(TIME) remains understudied. Here, we elucidate function and mechanism of YTH N6 …

[HTML][HTML] RAS: Striking at the Core of the Oncogenic Circuitry

RC Gimple, X Wang - Frontiers in oncology, 2019 - frontiersin.org
Cancer is a devastating disease process that touches the lives of millions worldwide.
Despite advances in our understanding of the genomic architecture of cancers and the …

[HTML][HTML] Invasive lobular carcinoma of the breast: morphology, biomarkers and'omics

AEMC Reed, JR Kutasovic, SR Lakhani… - Breast cancer …, 2015 - Springer
Invasive lobular carcinoma of the breast is the most common 'special'morphological subtype
of breast cancer, comprising up to 15% of all cases. Tumours are generally of a good …

[HTML][HTML] Next-generation sequencing to guide cancer therapy

J Gagan, EM Van Allen - Genome medicine, 2015 - Springer
As a result of multiple technological and practical advances, high-throughput sequencing,
known more commonly as “next-generation” sequencing (NGS), can now be incorporated …